Combinatorial Enzyme Therapy Against ESKAPE Pathogenic Biofilms

Dr. Awanish Kumar is an Associate Professor of the Department of Biotechnology at the National Institute of Technology, Raipur, Chhattisgarh, India. He has more than 13 years of research experience. He received his PhD in molecular parasitology from the CSIR-Central Drug Research Institute, Lucknow, India, and Jawaharlal Nehru University, Delhi, India, and completed his postdoctoral studies at McGill University, Montreal, Canada. His research interests are infection biology, drug targeting, and drug discovery. Aditya Upadhyay is a researcher at the Department of Biotechnology, National Institute of Technology in Raipur, India. His research focuses on infection biology, antibiotic resistance, and drug discovery in relation to biofilm formation. He holds a PhD in Biotechnology from the National Institute of Technology in Raipur, Master of Technology degree in Biotechnology (Honors) from Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal, India and a Bachelor of Technology in Biotechnology from Dr. A.P.J Abdul Kalam Technical University, Lucknow, India. Aditya is currently working on the design of new drugs and therapies to treat salmonella biofilm infections and combat antibiotic resistance. He has published articles in various SCI journals and contributed book chapters.

• 1. Introduction to Biofilm and Antibiotic Resistance in ESKAPE Pathogen-Associated Diseases: Clinical Burden and Challenges2. Burden of ESKAPE Pathogens in the Food Industry3. Co-relationship between Antibiotic Resistance and ESKAPE Pathogen Biofilm Formation4. The Necessity of Combinatorial Enzymatic Therapy for ESKAPE Pathogen Biofilm Control5. Mechanisms of Combinatorial Enzyme Therapy against the ESKAPE Pathogen Biofilm6. Combinatorial Enzyme against ESKAPE Pathogen Biofilms: Carbohydrase, Protease, and Lipase Synergies7. Combinatorial Nuclease Enzymes against ESKAPE Pathogen Biofilms with Clinical Application8. Therapeutic Enzymatic Repurposing against the ESKAPE Pathogen Biofilm with Clinical Application9. Nano Delivery of the Combinatorial Enzymes against the ESKAPE Pathogen Biofilm10. CRISPR-Cas Systems and Artificial Intelligence Drive Combinatorial Enzyme Therapy against the ESKAPE Pathogen Biofilm11. Future of Advanced Combinatorial Enzyme Therapy with Regulatory Aspects against the ESKAPE Pathogen Biofilm